Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김근호 | - |
dc.date.accessioned | 2019-12-07T19:04:29Z | - |
dc.date.available | 2019-12-07T19:04:29Z | - |
dc.date.issued | 2018-04 | - |
dc.identifier.citation | JOURNAL OF KOREAN MEDICAL SCIENCE, v. 33, no. 15, Article no. UNSP e112 | en_US |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.issn | 1598-6357 | - |
dc.identifier.uri | https://jkms.org/DOIx.php?id=10.3346/jkms.2018.33.e112 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/118320 | - |
dc.description.abstract | Background: The aim of this multicenter study was to evaluate the safety and efficacy of tolvaptan (TLV) in Korean patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).Methods: Of 51 enrolled patients with SIADH, 39 patients (16 female patients, aged 70.8 +/- 11.3 years) were included in an intention to treat analysis. All patients received 15 mg/day as the initial dose, and the dose was then increased up to 60 mg/day (as needed) until day 4.Results: Serum sodium increased significantly from baseline during the first 24 hours (126.8 +/- 4.3 vs. 133.7 +/- 3.8 mmol/L, P < 0.001), rose gradually between days 1 and 4 (133.7 +/- 3.8 vs. 135.6 +/- 3.6 mmol/L, P < 0.05), and then plateaued until day 11 (136.7 +/- 4.5 mmol/L). The correlation between the change in serum sodium for the first 24 hours and initial serum sodium concentration was significant (r = -0.602, P < 0.001). In severe hyponatremia (< 125 mmol/L), the change was significantly higher (11.1 +/- 4.8 mmol/L) than in moderate (6.4 +/- 2.5 mmol/L, P < 0.05) or mild hyponatremia (4.3 +/- 3.3 mmol/L, P < 0.01). In addition, logistic regression analysis showed that body weight (odds ratio [OR], 0.858; 95% confidence interval [CI], 0.775-0.976; P = 0.020) and body mass index (BMI) (OR, 0.692; 95% CI, 0.500-0.956; P = 0.026) were associated with rapid correction. No serious adverse events were reported, but in 13% of patients hyponatremia was overcorrected.Conclusion: TLV is effective in correcting hyponatremia and well-tolerated in Korean patients with SIADH. However, those with low body weight, low BMI or severe hyponatremia, could be vulnerable to overcorrection with the initial dose of 15 mg TLV. | en_US |
dc.description.sponsorship | This study was funded by Korea Otsuka Pharmaceutical Co., Ltd. in 2012, | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | en_US |
dc.subject | Hyponatremia | en_US |
dc.subject | Inappropriate ADH Syndrome | en_US |
dc.subject | Tolvaptan | en_US |
dc.title | Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone | en_US |
dc.type | Article | en_US |
dc.relation.no | 15 | - |
dc.relation.volume | 33 | - |
dc.identifier.doi | 10.3346/jkms.2018.33.e112 | - |
dc.relation.page | 112-122 | - |
dc.relation.journal | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.contributor.googleauthor | Han, Sang Woong | - |
dc.contributor.googleauthor | Yi, Joo Hark | - |
dc.contributor.googleauthor | Kang, Kyung Pyo | - |
dc.contributor.googleauthor | Kim, Ha Yeon | - |
dc.contributor.googleauthor | Kim, Soo Wan | - |
dc.contributor.googleauthor | Choi, Hoon Young | - |
dc.contributor.googleauthor | Ha, Sung-Kyu | - |
dc.contributor.googleauthor | Kim, Gheun-Ho | - |
dc.contributor.googleauthor | Kim, Yang Wook | - |
dc.contributor.googleauthor | Jeong, Kyung Hwan | - |
dc.relation.code | 2018003141 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | kimgh | - |
dc.identifier.orcid | http://orcid.org/0000-0002-8445-9892 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.